Antileukotrienes in Upper Airway Inflammatory Diseases

CİNGİ C., MULUK N. B., Ipci K., Sahin E.

CURRENT ALLERGY AND ASTHMA REPORTS, cilt.15, sa.11, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 15 Sayı: 11
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s11882-015-0564-7
  • Dergi Adı: CURRENT ALLERGY AND ASTHMA REPORTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Leukotrienes, Antileukotriene drugs, Asthma, Chronic rhinosinusitis with nasal polyposis, Allergic rhinitis, LEUKOTRIENE RECEPTOR ANTAGONIST, SEASONAL ALLERGIC RHINITIS, CHRONIC HYPERPLASTIC SINUSITIS, CYSTEINYL LEUKOTRIENES, NASAL POLYPOSIS, MESSENGER-RNA, DOUBLE-BLIND, GM-CSF, MONTELUKAST, ASTHMA
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Leukotrienes (LTs) are a family of inflammatory mediators including LTA(4), LTB4, LTC4, LTD4, and LTE4. By competitive binding to the cysteinyl LT1 (CysLT(1)) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allergic rhinitis. We reviewed the efficacy of antileukotrienes in upper airway inflammatory diseases. An update on the use of antileukotrienes in upper airway diseases in children and adults is presented with a detailed literature survey. Data on LTs, antileukotrienes, and antileukotrienes in chronic rhinosinusitis and nasal polyps, asthma, and allergic rhinitis are presented. Antileukotriene drugs are classified into two groups: CysLT receptor antagonists (zafirlukast, pranlukast, and montelukast) and LT synthesis inhibitors (5-lipoxygenase inhibitors such as zileuton, ZD2138, Bay X 1005, and MK-0591). CysLTs have important proinflammatory and profibrotic effects that contribute to the extensive hyperplastic rhinosinusitis and nasal polyposis (NP) that characterise these disorders. Patients who receive zafirlukast or zileuton tend to show objective improvements in, or at least stabilisation of, NP. Montelukast treatment may lead to clinical subjective improvement in NP. Montelukast treatment after sinus surgery can lead to a significant reduction in eosinophilic cationic protein levels in serum, with a beneficial effect on nasal and pulmonary symptoms and less impact in NP. Combined inhaled corticosteroids and long-acting beta-agonists treatments are most effective for preventing exacerbations among paediatric asthma patients. Treatments with medium-or high-dose inhaled corticosteroids, combined inhaled corticosteroids and LT receptor antagonists, and low-dose inhaled corticosteroids have been reported to be equally effective. Antileukotrienes have also been reported to be effective for allergic rhinitis.